Olema Pharmaceuticals, INC. (OLMA) — 10-Q Filings

10-Q Filings (5)

• Olema's Q3 Loss Widens on Increased R&D Spend — Nov 10, 2025 Risk: high
  Olema Pharmaceuticals, Inc. (OLMA) reported a net loss of $42.217 million for the three months ended September 30, 2025, an increase from $34.555 million in the
• Olema's Losses Widen Amid Increased R&D Spend — Aug 11, 2025 Risk: high
  Olema Pharmaceuticals, Inc. reported a net loss of $60.3 million for the six months ended June 30, 2025, a significant increase from the $49.2 million net loss
• Olema Pharma Q1 2025 Update — May 13, 2025 Risk: medium
  Olema Pharmaceuticals, Inc. filed its quarterly report for the period ending March 31, 2025. The company reported financial data including retained earnings and
• Olema Pharma Q3 2024: $105.4M Cash, Novartis & Aurigene Deals — Nov 12, 2024 Risk: medium
  Olema Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported cash and cash equivalents of $105.4 million as of Sept
• Olema Pharmaceuticals Files 10-Q for Period Ending March 31, 2024 — May 8, 2024 Risk:
  Olema Pharmaceuticals, Inc. (OLMA) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Olema Pharmaceuticals reported financial results for the quarter

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX